Fig. 1

Clinical characteristics of patients aged 0–18 with the SARS-CoV-2 Omicron subvariant BA.5.2 in Guangzhou. a The number of pediatric and adolescent patients with the BA.5.2 strain of COVID-19 in four age groups. Patient numbers are shown above each group. b The percentages of patients in four age groups who have received a SARS-CoV-2 vaccine. c The percentages of asymptomatic, mild, and moderate cases of the BA.5.2 strain of COVID-19 in patients aged 0–18 years. d The rates of fever, cough, expectoration, and diarrhea in patients aged 0–18 years and the rates of throat discomfort, headache, muscle or joint pain, tiredness, and hyposmia in patients with BA.5.2 in patients aged 4–18 years. e, f Fever peaks and fever duration (in days) in BA.5.2 patients of four age groups. Patient numbers are shown below each group. g The kinetics of SARS-CoV-2 RNA clearance. Cumulative viral clearance (%) is shown. The abscissa represents the time required for negative conversion of nucleic acid and the ordinate represents the percentages of patients with negative nucleic acid. The calculation method for viral RNA clearance was: viral RNA clearance (%) = the number of patients whose nucleic acid turned negative/total number of patients × 100%. P-values (derived by log-rank [Mantel-Cox] test) are shown. h Time for viral clearance. i. Peak viral load. The maximum viral load (represented by the lowest Ct value) of each patient during hospitalization was identified. Patient numbers are shown below each group. Each dot represents one patient. The Mann–Whitney U-test was used for (e), (f), (h) and (i); p-values <0.05 were deemed statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001). 0–3 y, patients aged 0–3 years old; 4–6 y, patients aged 4–6 years old; 7–14 y, patients aged 7–14 years old; 15–18 y, patients aged 15–18 years old. 0-dose, not vaccinated; 2-dose, received two doses of the vaccine; 3-dose, received three doses of the vaccine. Ct, cycle threshold; RNA, ribonucleic acid; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2